Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

A universally accessible residual Network–Assisted diagnostic and analytic tool (RADIANT) for acute lymphoblastic leukemia

Jansi Sethuraj, Ramya Elangovan, Gowrishankar Palaniswamy et al. Nov 03, 2025 pp. 6142-6142 10.1182/blood-2025-6142

Abstract Background: Acute lymphoblastic leukemia (ALL) remains the predominant pediatric malignancy and poses significant therapeutic chall...

Silver nanoparticles trigger proteotoxicity in multiple myeloma cells via a mechanism distinct from bortezomib and remain efective in BTZ-resistant myeloma

Khushbu Patel, Lawrence Druhan, Timothy Pardee et al. Nov 03, 2025 pp. 4322-4322 10.1182/blood-2025-4322

Abstract Background: Multiple myeloma (MM), characterized by abnormal clonal plasma cell expansion, is the second most common hematologic ma...

The discovery of crotonoside as a nucleoside analogue demonstrates its potential to inhibit acute myeloid leukemia  activity through multiple pathways

Chenchen Ma, Jingyi Wang Nov 03, 2025 pp. 6790-6790 10.1182/blood-2025-6790

Abstract Acute myeloid leukemia (AML) is a type of malignant neoplasm that affects hematopoietic stem and progenitor cells, characterized by...

Molecular stratification of relapse risk post-allogeneic hematopoietic stem cell transplantation in myeloid neoplasms with non-adverse risk cytogenetics

Khalid Abu-Zeinah, Anmol Baranwal, Khalil Hassan et al. Nov 03, 2025 pp. 6073-6073 10.1182/blood-2025-6073

Abstract Background: Disease relapse is a major cause of mortality post allogeneic hematopoietic stem cell transplantion (alloHCT) in patien...

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies

Peter Miller, Ygang Tang, David McKinney et al. Nov 03, 2025 pp. 5048-5048 10.1182/blood-2025-5048

Abstract Background and Objective: Cytotoxic chemotherapy remains a foundational treatment for many cancers, yet its effectiveness is often...

Combining mertk inhibitor mrx-2843 with venetoclax and 5-azacitidine in AML

Aashis Thapa, Edward Henderson, Austre Y. Schiaffino Bustamante et al. Nov 03, 2025 pp. 6795-6795 10.1182/blood-2025-6795

Abstract Introduction: Acute myeloid leukemia (AML) is the most aggressive form of leukemia, and therapies that can sustain long-term cures...

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Zachary Frosch, Anthony Masaquel, Esprit Ma et al. Nov 03, 2025 pp. 2622-2622 10.1182/blood-2025-2622

Abstract Background: In our recent study, fixed duration BsAbs (glofitamab [Glofit] and mosunetuzumab [Mosun]) with less frequent dosing wer...

Predictors of outcome in adult patients with Relapsed/Refractory T-cell acute lymphoblastic leukemia

Vanthana Bharathi, Nitin Jain, Elias Jabbour et al. Nov 03, 2025 pp. 5112-5112 10.1182/blood-2025-5112

Abstract Background: The outcome of adult patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) remains poor w...

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Remy Dulery, Mathilde Fekom, Catherine Thieblemont et al. Nov 03, 2025 pp. 2744-2744 10.1182/blood-2025-2744

Abstract Introduction Autologous hematopoietic stem cell transplantation (auto-HSCT) and chimeric antigen receptor (CAR) T-cell therapy are...

Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia

Robert Chiesa, Christos Georgiadis, Hebatalla Rashed et al. Nov 03, 2025 pp. 1041-1041 10.1182/blood-2025-1041

Abstract Background Base editing (BE) by cytidine deamination offers advantages over canonical clustered regularly interspaced short palindr...

Adverse events reported with eltrombopag and romiplostim: Faers database

Shivani Modi, Charishma Bhimineni, Manasa Anipindi et al. Nov 03, 2025 pp. 4815-4815 10.1182/blood-2025-4815

Abstract Background: Eltrombopag and romiplostim are thrombopoietin receptor agonists approved for treating thrombocytopenia in various cond...

Cause of non-cancer related death among patients diagnosed with lymphoid neoplasm: A SEER-based study

Nikita Tripathi, Connor Yost, Edward Cao et al. Nov 03, 2025 pp. 2783-2783 10.1182/blood-2025-2783

Abstract Introduction In the United States in 2024, around 89,190 adults were newly diagnosed with lymphoma and approxim...

Long-term imatinib therapy leads to significant reduction in GFR

Sanjeevan Sharma, Rajan Kapoor, Kundan Mishra et al. Nov 03, 2025 pp. 2005-2005 10.1182/blood-2025-2005

Abstract Background Chronic Myeloid Leukemia (CML) is primarily treated with Tyrosine Kinase Inhibitors (TKIs), with Ima...

A genetic comparison of epstein-barr virus-associated polymorphic lymphoproliferative disorder and diffuse large B cell lymphoma

Jennifer Chapman, Evgeniia Alekseeva, Anna Tarasova et al. Nov 03, 2025 pp. 1776-1776 10.1182/blood-2025-1776

Abstract Background: Epstein-Barr Virus (EBV) is a potent transforming oncovirus causally associated with development of cancer including ly...

Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF)

Chiara Paoli, Paola Guglielmelli, Giulia Borgi et al. Nov 03, 2025 pp. 5527-5527 10.1182/blood-2025-5527

Abstract Background. The neutrophil-to-lymphocyte ratio (NLR) has received considerable interest as a simple and reliable marker of disease...

Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study

Yan Zhang, Huiying Zhu, Zhangyuting He et al. Nov 03, 2025 pp. 5471-5471 10.1182/blood-2025-5471

Abstract Background:High-dose methotrexate (HD-MTX) is widely used as front-line treatment in patients with primary central nervous system l...

Clinical validation of a high sensitivity method to detect residual disease in blood of treated myeloma patients

David Murray, Mindy Kohlhagen, Maria Alice Willrich et al. Nov 03, 2025 pp. 5800-5800 10.1182/blood-2025-5800

Abstract Introduction In 2018, our institution implemented a MALDI-TOF mass spectrometry (MS) method (Mass-Fix) to detect myeloma associated...

Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation

Erlie Jiang, Chen Liang, Donglin Yang et al. Nov 03, 2025 pp. 2519-2519 10.1182/blood-2025-2519

Abstract Background Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) muta...

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Conal Houstoun, Patrick Hayden, Dirk-Jan Eikema et al. Nov 03, 2025 pp. 4583-4583 10.1182/blood-2025-4583

Abstract Introduction Approximately 10% of patients with newly diagnosed multiple myeloma (MM) have the FISH cytogenetic abnormality, Del 17...

Timed inhibition of the sting pathway improves tissue regeneration and prevents GVHD following allo-HSCT

Sascha Göttert, Chiara Suriano, Omer Khalid et al. Nov 03, 2025 pp. 2317-2317 10.1182/blood-2025-2317

Abstract Background: Graft-versus-host disease (GVHD) is a severe complication of allogeneic stem-cell transplantation (...

Clonal persistence of BRAFV600E under MEK inhibition in histiocytosis

Marzieh Nashvi, David Fandrei, Florian Houdu et al. Nov 03, 2025 pp. 1495-1495 10.1182/blood-2025-1495

Abstract BackgroundLangerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare histiocytic disorders driven by activation...

AI-based diagnosis of cutaneous lymphoma and lymphoproliferative disorders via H&E morphology and LLM-assisted cohort curation

Ali Kamali, Khawaja Bilal, Zhanghan Yin et al. Nov 03, 2025 pp. 2564-2564 10.1182/blood-2025-2564

Abstract Background: Cutaneous T-cell lymphomas (CTCLs) and cutaneous lymphoproliferative disorders (CLPD) are diagnostically challenging cl...

Virma epitranscriptomically regulates cell proliferation, apoptosis, and mitochondrial function via m6A in multiple myeloma

Estibaliz Urizar Compains, Naroa Barrena, Theodore Maximilian Nelson et al. Nov 03, 2025 pp. 3255-3255 10.1182/blood-2025-3255

Abstract Multiple Myeloma (MM) is a hematological neoplasm characterized by the clonal expansion of malignant plasma cells (PCs) within the...

Trends in leukemia mortality among adults with cardiovascular disease in the United States, 1999–2024: An analysis of the CDC wonder database

Janta Ukrani, Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan et al. Nov 03, 2025 pp. 8189-8189 10.1182/blood-2025-8189

Abstract Background: Leukemia remains a significant contributor to cancer-related mortality, with cardiovascular diseases (CVDs) commonly oc...

Real-world burden and risk analysis of hematologic iraes in patients treated with immune checkpoint inhibitors: 5-year cohort study

Ali Awada, Abbas Hammoud, Mohammad Kassem et al. Nov 03, 2025 pp. 4471-4471 10.1182/blood-2025-4471

Abstract Introduction Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and prognosis of multiple solid tumors like mela...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page